drugset / Trial / NCT00351767

A Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor for Induction of Healing of Diabetic Foot Ulcers

NCT00351767 ↗

Phase 2 Completed 170 enrolled Genentech, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of three different doses of topically applied telbermin in subjects ≥ 18 years old with diabetic foot ulcers. Approximately 160 adult subjects with Type 1 or Type 2 diabetes mellitus will be enrolled at approximately 40 investigational sites in the United States and Canada.

Timeline

Start
2006-01
Primary completion
2008-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject sNN0029 Unknown — Other

Indications